AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02674776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Patients should take 4 tablet once and 3 times per day for 3 days.
Study NCT03516812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03516812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT03516812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03516812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03516812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: Given IM
Study NCT03516812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cypionate
Description: Given IM
Study NCT03951714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Marketed experience application on adherence
Description: To evaluate the effect of electronic capture of medication intake through a smartphone app on treatment's adherence
Study NCT03951714 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Marketed experience application on adherence
Description: To evaluate the effect of electronic capture of medication intake through a smartphone app on treatment's adherence
Study NCT02416219 — intervention group
Intervention type: PROCEDURE
Intervention: Cricoid pressure
Description: participants will ask to mark the place where they will apply cricoid pressure if the patients was undergoing rapid sequence induction. US will be used to confirm how accurate they are in their estimation.
Study NCT02416219 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Study NCT03991858 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phone call follow-up
Description: A physical therapist made a phone call to the patient one month after his/her initial evaluation at the external rehabilitation clinic
Study NCT03991858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation follow-up
Description: A physical therapist made a direct follow-up through telerehabilitation to the patient one month after his/her initial evaluation at the external rehabilitation clinic
Study NCT03439657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine GSK1437173A
Description: 2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.
Study NCT03439657 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HZ/su vaccine GSK1437173A
Description: 2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.
Study NCT03439657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar13
Description: 1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.
Study NCT03439657 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13
Description: 1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.
Study NCT04273373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose Albumin
Description: 20% albumin 0.75 g/kg at diagnosis and 0.5 g/kg after 48 hours
Study NCT04273373 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose Albumin
Description: 20% albumin1.5 g/kg at diagnosis and 1 g/kg after 48 hours (duration of infusion 6 hours).
Study NCT05460260 — intervention group
Intervention type: DEVICE
Intervention: Cascade CGM
Description: 21-days of CGM wear
Study NCT03945266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: During the intervention, all participants will start out at the Baseline level. The baseline level will last 2 weeks and there will be an assessment to determine weight gain over those 2 weeks. If weight gain has succeeded the recommended amount, participants will be adapted up to a new level of intervention that includes education on GWG, healthy eating and physical activity. After every 4 weeks, an assessment will be performed and adaptations up will be made if necessary. Adaptations include addition of exercise sessions, healthy eating recipe demonstrations, and meal replacements. Participants will weigh themselves daily, wear an activity monitor, record their diet, and complete paper and online surveys.
Study NCT03945266 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Participants will follow the same self-monitoring/assessment schedule but will not receive the GWG, healthy eating, and physical activity education or adaptations.
Study NCT03206437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: The MBSR course teaches mindfulness meditation skills. This 8-week course meets in person once a week for 2.5 hours. Participants are expected to complete practice assignments at home.
Study NCT03206437 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist
Description: This group will wait 8-16 weeks after their first testing visit and after their second study visit is completed they will be able to participate in an 8-week MBSR course.
Study NCT04117139 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/MRI
Description: A PET/MRI of the Head and Neck region is done for all patients included in the project.
Study NCT02362178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thromboelastography to guide blood products infusion
Description: A TEG has been performed before invasive procedure and blood products infusion has been decided according to TEG parameters as follow: fresh frozen plasma (FFP 10 ml/kg) in case of r time>40 mm and/or platelets (PLTs 10 units/Kg) for MA\<30 mm
Study NCT02362178 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care coagulation tests to guide blood products infusion
Description: Patients received FFP (10 ml/kg) if INR>1.8 and/or PLTS (10 units/Kg) If PLTs count \< 50000/μl
Study NCT03727425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic assisted bronchoscopy
Description: Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
Study NCT01945827 — intervention group
Intervention type: DEVICE
Intervention: DeltaMaxx Microcoil System
Study NCT02827916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of neuropathic pain with theThermotest device
Description: Measure of painful neuropathy with thermotest
Study NCT02827916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of neuropathic pain with SUDOSCAN device
Description: Measure of painful neuropathy with sudoscan Devices
Study NCT02827916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of neuropathic pain with the Neuropathic Pain Symptom Inventory.
Description: Measure of painful neuropathy with Neuropathic Pain Symptom Inventory.
Study NCT02933112 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Auto-titrating mandibular positioner test
Description: Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
Study NCT04183062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (gemcitabine & docetaxel) plus BIO-11006
Description: BIO-11006 will be administered at a dose of 75 mg twice daily for patients over 5 years of age and under 18 years of age or 125 mg twice daily for patients 18 years of age or older. The study drug will be administered twice daily by nebulizer over 20 minutes.~GemTax will be administered in 21-day cycles. Gemcitabine will be administered at a dose of 900 mg/m2 IV over 90 minutes on days 1 and 8. Docetaxel will be administered at a dose of 75 mg/m2 IV over 60 minutes on day 8.
Study NCT02521493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IM or IV
Study NCT02521493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia chrysanthemi
Description: Given IM or IV
Study NCT02521493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV
Study NCT02521493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT02521493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02521493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02521493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study NCT02521493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO
Study NCT00003700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 300mg PO q day Days 1-14 Course I
Study NCT01658995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline 100 mg oral capsules twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
Study NCT01658995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, one capsule orally twice daily for 10 days. After 10 days, an additional Secondary treatment may be requested.
Study NCT00998595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Promotora
Description: The Promotora will deliver education regarding postpartum follow-up and steps to take to decrease the risk for developing type 2 diabetes. The Promotora will clarify misperceptions and answer questions related to risk of developing diabetes and contraception. If the subject has barriers to accessing care with transportation or childcare, she will help the subjects to access existing resources. The Promotora will give the subject her contact information and will also contact the subject to remind her of her appointments and reschedule if she missed an appointment.
Study NCT00912522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: TRANSCRANIAL MAGNETIC STIMULATION
Study NCT01090609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent implantation
Description: Stent implantation
Study NCT00372216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel (Iscover/Plavix)
Description: Pre-hospital loading-dose of 600 mg Clopidogrel as early as possible
Study NCT04269850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic fecal microbiota
Description: Single dose of capsules with fecal transplant (capsules for adults - 400-815mg, for adolescents - 280-500mg, for children - 160-320mg) - 2 capsules/kg body weight, divided in two consecutive days Additional supportive therapy after FMT include omeprazole 40mg po, inulin 1gr x 4 times a day po, metoclopramide 40mg po.
Study NCT04269850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib starting dose 10 mg bid. In case of grade 4 hematological toxicity dose can be reduced by 25-75%.
Study NCT04269850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisone
Description: Methylprednisone starting dose 0.5 mg/kg bid IV or oral, with subsequent tapper by 0.1 mg/kg every 5 days.
Study NCT01299987 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intraoperative radiotherapy
Description: intraoperative single dose radiotherapy (20 Gy)
Study NCT00912522 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: TRANSCRANIAL MAGNETIC STIMULATION
Study NCT03108820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TMH Intervention
Description: Home visits and close interaction with injured patient to assure plan for care is being followed.
Study NCT03108820 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Review hospital discharge and rehabilitation plan, identification of primary care provider, provision of educational materials on communication skills, caregiver coping skills, and legal and financial advice.
Study NCT01792453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spring water
Study NCT01775722 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pulsed Dye Laser
Description: port wine stain
Study NCT01775722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined Bipolar Radiofrequency&Pulsed Dye Laser
Description: Combined Bipolar Radiofrequency\&Pulsed Dye Laser Treatment
Study NCT03014414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fun First
Description: Learn key enjoyable maintenance skills before losing weight
Study NCT03014414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Watchers
Description: Focus on losing weight first via convenient meetings and personalized online tools
Study NCT03790956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Silk Microparticle Filler Injection
Description: A silk protein microparticle-based filler will be injected deep to the thyroarytenoid muscle of the paralyzed vocal fold to augment/medialize its position.
Study NCT04033510 — intervention group
Intervention type: OTHER
Intervention: Standard of Care Interventions to convert patient from atrial fibrillation to normal rhythm
Description: Direct current cardioversion, PVAI-atrial fibrillation ablation, Minimally Invasive Surgical Maze procedure, Medications
Study NCT06400251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06400251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06400251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06400251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Given PO
Study NCT06400251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT00309738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin
Study NCT00309738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Study NCT01632046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactate and bicarbonate buffered dialysis solutions
Description: Either PD-solution will be applied. Number of cycles and glucose concentration will be varied according to clinical needs. Sleep Safe system will be used and connected to Sleep Safe Cyclers in patient on CCPD.
Study NCT05979285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: N1-Headache App (by Curelator)
Description: Digital application allowing patients to monitor their migraines, and to identify triggers and/or protectors for their migraines.
Study NCT04574323 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Curative radiotherapy
Description: Standard curative radiotherapy
Study NCT04574323 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Curative radiotherapy
Description: Standard curative radiotherapy
Study NCT04574323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paleolithic lifestyle intervention
Description: This intervention consists of daily outdoor walks or bike rides of at least 30 min duration, preferably done at noon to maximize vitamin D production, and the adoption of a Paleolithic diet. For the outdoor activity, patients were told to not use sun screen. The Paleolithic diet prescription emphasized the consumption of fatty meats and organ meats from humanely raised animals, wild-caught fish, eggs, nuts and seeds, algae, spices, vegetables and fruits. Excluded were processed foods, grains of all types, legumes, vegetable oils except for native coconut and olive oil and dairy products except for ghee. No dietary supplements were allowed.
Study NCT04267003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
Study NCT04267003 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (\~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (\~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
Study NCT04268264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incremental haemodialysis
Description: twice weekly haemodilysis at the start, gradually building up to full dose dialysis over a period of 15 weeks
Study NCT03078907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.
Study NCT03078907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching film coated tablets
Study NCT02059811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH Diet
Description: The DASH diet is a nutritional intervention that is low in cholesterol and saturated fat and emphasizes high intake of the following: fruits, vegetables, low-fat dairy products, whole grains, fiber, and protein derived mostly from plant sources.
Study NCT02059811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Diet
Description: The control diet, which is a diet typical of most Americans, is relatively high in total and saturated fat and cholesterol, and low in servings of fruits, vegetables and low fat dairy products.
Study NCT02828566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN ketamine
Description: Intranasal ketamine 100 mg/mL solution (10 mg/kg, maximum 800 mg)
Study NCT00891462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Aclidinium bromide 200 μg, oral inhalation twice per day for 12 weeks of treatment
Study NCT00891462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Aclidinium bromide 400 μg, oral inhalation twice per day for 12 weeks of treatment
Study NCT00891462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo, oral inhalation twice per day for 12 weeks of treatment
Study NCT01757262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mg Ticagrelor
Description: Morning and Evening dose for 5 days
Study NCT01757262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 75mg Clopidogrel
Description: Morning dose for 5 days
Study NCT01645904 — intervention group
Intervention type: BEHAVIORAL
Intervention: Audiotaped Focus Group
Description: Participation in a focus group regarding web-based program designed to improve communication of health and health history information among family members affected by Lynch syndrome.
Study NCT01645904 — intervention group
Intervention type: BEHAVIORAL
Intervention: Demographic Questionnaire
Description: Complete questions about demographics (age, race, marital status) and medical history. This visit should take about 1 hour to complete.
Study NCT02828566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV ketamine
Description: Intravenous ketamine 50 mg/mL solution (1 to 1.5 mg/kg, maximum 120 mg)
Study NCT02828566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IN saline 0.9%
Description: Intranasal 0.9% normal saline
Study NCT02828566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV saline 0.9%
Description: Intravenous 0.9% normal saline
Study NCT01645904 — intervention group
Intervention type: BEHAVIORAL
Intervention: Audiotaped Interview
Description: Group 2: Patients provide feedback regarding initial version of My Family Garden website.~Group 3: Patients provide feedback regarding final version of My Family Garden website.
Study NCT01645904 — intervention group
Intervention type: BEHAVIORAL
Intervention: WAMMI Inventory
Description: Patients complete Website Analysis and MeasureMent Inventory. This visit should take about 90 minutes to complete.
Study NCT01964131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H sachet 20 mg
Description: Each subject will be randomised evenly to one of Treatment: A-->B (Sequence 1) or Treatment: B-->A (Sequence 2).~Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg